Table 3.
Comparison between demographic and clinicopathological features of SPTC, FPTC-2 and FPTC−3 patients
| Parameters | SPTC (n = 630) | FPTC-2 (n = 79) | FPTC−3 (n = 22) | p |
|---|---|---|---|---|
| Gender, n (%) | 0.99 | |||
| Female | 466 (74) | 59 (74.7) | 6 (27.3) | |
| Age at diagnosis, years | 0.42 | |||
| Mean ± SD | 46.6±15.6 | 44.4±16.9 | 44.5±10.2 | |
| Range | 7−82 | 14−81 | 23−70 | |
| Median | 46 | 43 | 45 | |
| Tumour diameter, cm | 0.02a, b | |||
| Mean ± SD | 1.6±1.2 | 1.6±1.2 | 1.0±0.8 | |
| Range | 0.1−7.2 | 0.1−6.5 | 0.2−3 | |
| Median | 1.3 | 1.2 | 0.8 | |
| Multifocality, n (%) | 0.23 | |||
| Yes | 238 (37.8) | 39 (49.4) | 8 (36.4) | |
| Bilaterality, n (%) | 0.03 | |||
| Yes | 168 (26.7) | 33 (41.8) | 7 (31.8) | |
| Tumour extension, n (%) | 0.85 | |||
| Extrathyroidal | 227 (36.1) | 34 (43.0) | 6 (27.3) | |
| Lymph node dissection, n (%) | 0.84 | |||
| Therapeutic | 100 (15.9) | 16 (20.2) | 4 (18.2) | |
| Prophylactic | 52 (8.3) | 6 (7.6) | 2 (9.1) | |
| Not Performed | 478 (75.8) | 57 (72.2) | 16 (72.7) | |
| Lymph node metastases, n (%) | 0.63 | |||
| Yes | 159 (25.2) | 22 (27.8) | 6 (27.3) | |
| ATA risk class, n (%) | 0.71 | |||
| High/intermediate | 303 (48.1) | 41 (51.9) | 8 (36.4) | |
| Low risk | 327 (51.9) | 38 (48.1) | 14 (63.6) | |
| Radioiodine ablation, n (%) | 0.28 | |||
| Yes | 504 (80.5) | 73 (92.4) | 16 (72.7) | |
| Doses of ablative 131I (mCi), n (%) | 0.13 | |||
| Mean ± SD | 70.5±33.9 | 77.5±48.4 | 54.6±29.6 | |
| Range | 15−300 | 15−300 | 30−100 | |
| Median | 65 | 75.5 | 50 | |
| Cumulative activity of 131I (mCi), n (%) | 0.18 | |||
| Mean ± SD | 129.9±186.0 | 157±189.4 | 164.5±127.6 | |
| Range | 15−1300 | 15−1056 | 30−460 | |
| Median | 80 | 100 | 150 | |
| Follow-up, years | 10.3±5.6 | 9.5±4.8 | 8.1±4.8 | 0.19 |
| Range | 2−56 | 2−25 | 2−20 | |
| Median | 10 | 9 | 8 | |
a
Significant difference between SPTC and FPTC−3 group.
b
Significant difference between FPTC-2 and FPTC−3 group.